β-CA-specific inhibitor dithiocarbamate Fc14–584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis

Inhibition of novel biological pathways in Mycobacterium tuberculosis (Mtb) creates the potential for alternative approaches for treating drug-resistant tuberculosis. In vitro studies have shown that dithiocarbamate-derived β-carbonic anhydrase (β-CA) inhibitors Fc14–594 A and Fc14–584B effectively...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Enzyme Inhib Med Chem
Auteurs principaux: Aspatwar, Ashok, Hammarén, Milka, Koskinen, Sanni, Luukinen, Bruno, Barker, Harlan, Carta, Fabrizio, Supuran, Claudiu T., Parikka, Mataleena, Parkkila, Seppo
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445161/
https://ncbi.nlm.nih.gov/pubmed/28629306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2017.1332056
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires